Fabio Moda
Has grant
Assistant professor of Clinical Biochemistry and Clinical Molecular Biology
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
About
Fabio Moda is an Assistant Professor of Clinical Biochemistry and Clinical Molecular Biology at the Università degli Studi di Milano, Italy. His research focuses on neurodegeneration, prion proteins, and innovative diagnostic methods for neurodegenerative diseases. Notable recent publications include studies on the role of prion proteins in neurodegeneration and the use of extracellular vesicles for drug delivery in Parkinson’s disease.
Recent Grants
Grant: Close
Refining the clinical diagnosis of MSA-C and MSA-P using olfactory mucosa and skin samples
Open Date: 2024-03-01
Close Date: 2025-02-01
Grant: Open
Chronic wasting disease threatens Fennoscandian reindeer – How will breeding for CWD-resilience affect genetic variation and fitness?
Open Date: 2024-01-01
Close Date: 2027-12-01
Grant: Close
Toward molecular profiling of Parkinson's disease in easily accessible biological matrices
Open Date: 2023-05-01
Close Date: 2025-04-01
Grant: Close
Exploring the olfactory mucosa, blood and urine for the identification of early biomarkers of Parkinson's disease, atypical parkinsonisms and neurocognitive disorders due to Lewy body disease
Open Date: 2023-04-01
Close Date: 2026-03-01
Grant: Close
Tau RT-QuIC analysis in skin biopsies: a potential novel and non-invasive biomarker for patients with tauopathies (- partner Besta -)
Open Date: 2023-02-01
Close Date: 2025-01-01
Articles (10)
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2023
Objective Currently, it is unknown whether infectious prions are present in peripheral tissues and biological fluids of patients affected by sporadic Creutzfeldt–Jakob disease (sCJD), the most common prion disorder in humans. This represents a potential risk for inter‐individual prion infection. The main goal of this study was to evaluate the presence of prions in urine of patients suffering from the major subtypes of sCJD. Methods Urine samples from sCJD patients spanning the six major subtypes were tested. As controls, we used urine samples from people affected by other neurological or neurodegenerative diseases as well as healthy controls. These samples were analyzed blinded. The presence of prions was detected by a modified version of the PMCA technology, specifically optimized for high sensitive detection of sCJD prions. Results The PMCA assay was first optimized to detect low quantities of prions in diluted brain homogenates from patients affected by all subtypes of sCJD spiked into healthy urine. Twenty‐nine of the 81 patients affected by sCJD analyzed in this study were positive by PMCA testing, whereas none of the 160 controls showed any signal. These results indicate a 36% sensitivity and 100% specificity. The subtypes with the highest positivity rate were VV1 and VV2, which combined account for about 15–20% of all sCJD cases, and no detection was observed in MV1 and MM2. Interpretation Our findings indicate that potentially infectious prions are secreted in urine of some sCJD patients, suggesting a possible risk for inter‐individual transmission. Prion detection in urine might be used as a noninvasive preliminary screening test to detect sCJD.
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (8)
Barbara Garavaglia
Fondazione IRCCS Istituto Neurologico Carlo Besta
Giuseppe Legname
Professor
Scuola Internazionale Superiore di Studi Avanzati
Claudio Soto
-
Luigi RUSSO
Università degli Studi di Napoli Federico II
Michela Palmisani
Università degli Studi di Pavia
Roberto Eleopra
Chief of Neurology Unit
Fondazione IRCCS Istituto Neurologico Carlo Besta
Edoardo Farnesi
Friedrich Schiller University Jena
Carla Isernia
Prof
Università degli Studi della Campania Luigi Vanvitelli
Make your next move.
Prepare your application
Review drafts before you send them.